Cogent Biosciences, Inc. 8-K

What Happened

• On May 5, 2026, Cogent Biosciences, Inc. (COGT) filed a Form 8-K (Item 2.02) to announce its financial results for the three months ended March 31, 2026. The company issued a press release reporting its quarterly results; that press release is attached to the filing and incorporated by reference.

Key Details

• Filing date: May 5, 2026 (Form 8-K, Item 2.02).
• Period covered: Three months ended March 31, 2026 (Q1 2026).
• Press release attached: Exhibit 99.1 contains the complete announcement.
• Technical exhibit: Cover page provided in Inline XBRL as Exhibit 104.
• Other corporate items: This filing reports quarterly results only; no CEO/CFO changes, mergers, or other material transactions were disclosed in this 8-K.

Why It Matters

• Quarterly results provide updated information on Cogent’s earnings, revenue, and financial condition, which investors use to assess near-term performance and validate the company’s progress. Because the 8-K attaches the press release but does not include detailed financial tables in the filing text, investors should review Exhibit 99.1 for the specific metrics, management commentary, and any guidance.